Key facts
- This page summarizes Scott L. Burrows's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
- 10 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Oct 2026, 21:29.
Scott L. Burrows - 30 Sep 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SYRE
- Reported as of
- 30 Sep 2026
- Net transaction value
- -$2,261,831
- SEC form
- 4
- Accepted by SEC
- 02 Oct 2026, 21:29:27 UTC
- Prior SEC filing
- 03 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Heidy King-Jones, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Scott L. Burrows filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 02 Oct 2026.
Change
- Previous filing in this sequence was filed on 03 Sep 2026.
- Current net transaction value: -$2,261,831.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001853327
Primary reporting owner
Burrows Scott L
- Relationship
- Chief Financial Officer
- Address
- 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
- Signature
- /s/ Heidy King-Jones, as Attorney-in-Fact
- Signature date
- 02 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SYRE
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +17,500
- Change %
- +22%
- Price
- $14.50*
- Shares after
- 97,262
- Date
- 30 Sep 2026
- Ownership
- Direct
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$1,573,075
- Shares
- -17,500
- Change %
- -18%
- Price
- $89.89
- Shares after
- 79,762
- Date
- 30 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
SYRE
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,500
- Change %
- +9.4%
- Price
- $14.50*
- Shares after
- 87,262
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$53,442
- Shares
- -600
- Change %
- -0.69%
- Price
- $89.07
- Shares after
- 86,662
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2, F3
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$135,405
- Shares
- -1,500
- Change %
- -1.7%
- Price
- $90.27
- Shares after
- 85,162
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2, F4
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$193,032
- Shares
- -2,100
- Change %
- -2.5%
- Price
- $91.92
- Shares after
- 83,062
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2, F5
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$285,449
- Shares
- -3,071
- Change %
- -3.7%
- Price
- $92.95
- Shares after
- 79,991
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2, F6
SYRE
transaction
Common Stock
Sale
- Transaction value
- -$21,428
- Shares
- -229
- Change %
- -0.29%
- Price
- $93.57
- Shares after
- 79,762
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F2, F7, F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -17,500
- Change %
- -5.2%
- Price
- $0.000000*
- Shares after
- 319,857
- Date
- 30 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- $14.50
- Footnotes
- F9
SYRE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -7,500
- Change %
- -2.3%
- Price
- $0.000000*
- Shares after
- 312,357
- Date
- 01 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $14.50
- Footnotes
- F2, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F2
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
Footnote F3
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F5
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F6
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F7
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F8
Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
Footnote F9
This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.